Citalopram (Celexa)
SSRI • Last reviewed 2025-09-26
General information
Citalopram is an SSRI indicated for major depressive disorder. It is valued for minimal drug–drug interactions but carries a dose-dependent QT prolongation warning.
Tablets (10, 20, 40 mg) and an oral solution allow once-daily dosing with or without food. FDA recommends a maximum of 40 mg/day in adults and 20 mg/day in patients ≥60 years, hepatic impairment, or CYP2C19 poor metabolizers.
Compared with other SSRIs, citalopram produces similar remission rates but may be less activating, making it useful in anxious or insomnia-prone patients when dosed at night.
Clinicians should monitor electrolytes and ECG in patients with cardiac disease, bradycardia, or concomitant QT-prolonging medications.
Dosing & administration
Start 20 mg once daily; evaluate response after 4 weeks.
Increase to 40 mg/day if needed and if QT risk is low.
Do not exceed 20 mg/day in patients ≥60 years, hepatic impairment, CYP2C19 poor metabolizers, or taking CYP2C19 inhibitors.
Mechanism of action
Selective inhibition of the serotonin transporter with minimal affinity for muscarinic, histamine, or adrenergic receptors.
Metabolism & pharmacokinetics
Bioavailability ~80%; peak plasma levels 4 hours post-dose. Metabolized hepatically via CYP2C19, CYP3A4, and CYP2D6 to demethylated metabolites. Elimination half-life averages 35 hours (longer in elderly/hepatic impairment).
Drug interactions
Avoid MAOIs, linezolid, or methylene blue (serotonin syndrome).
CYP2C19 inhibitors (omeprazole, fluconazole) raise concentrations; limit to 20 mg/day.
QT-prolonging drugs (antiarrhythmics, antipsychotics) increase arrhythmia risk.
Monitoring & safety checks
Assessment of suicidality and activation
Serum sodium in older adults
Baseline and follow-up ECG in high-risk patients
Discontinuation guidance
Taper over at least 1–2 weeks; discontinuation symptoms are usually mild but may include dizziness, irritability, or paresthesias.
References
- Citalopram Prescribing Information — DailyMed
- APA Clinical Practice Guideline for Depression (2023)
- CANMAT 2024 Depression Guidelines (2024)
Educational use only — verify details in current prescribing information and authoritative clinical guidelines before making prescribing decisions.